Abstract

People with diabetes (PWD) have an increased risk of developing influenza-related complications, including pneumonia, abnormal glycemic events, and hospitalization. Annual influenza vaccination is recommended for PWD, but vaccination rates are suboptimal. The study aimed to increase influenza vaccination rate in people with self-reported diabetes. This study was a prospective, 1:1 randomized controlled trial of a 6-month Digital Diabetes Intervention in U.S. adults with diabetes. The intervention group received monthly messages through an online health platform. The control group received no intervention. Difference in self-reported vaccination rates was tested using multivariable logistic regression controlling for demographics and comorbidities. The study was registered at clinicaltrials.gov: NCT03870997. A total of 10,429 participants reported influenza vaccination status (5158 intervention, mean age (±SD) = 46.8 (11.1), 78.5% female; 5271 control, Mean age (±SD) = 46.7 (11.2), 79.4% female). After a 6-month intervention, 64.2% of the intervention arm reported influenza vaccination, vers us 61.1% in the control arm (diff = 3.1, RR = 1.05, 95% CI [1.02, 1.08], p = 0.0013, number needed to treat = 33 to obtain 1 additional vaccination). Completion of one or more intervention messages was associated with up to an 8% increase in vaccination rate (OR 1.27, 95% CI [1.17, 1.38], p < 0.0001). The intervention improved influenza vaccination rates in PWD, suggesting that leveraging new technology to deliver knowledge and information can improve influenza vaccination rates in high-risk populations to reduce public health burden of influenza. Rapid cycle innovation could maximize the effects of these digital interventions in the future with other populations and vaccines.

Details

Title
Digital intervention increases influenza vaccination rates for people with diabetes in a decentralized randomized trial
Author
Lee, J L 1   VIAFID ORCID Logo  ; Foschini, L 2   VIAFID ORCID Logo  ; Kumar, S 2 ; Juusola, J 2 ; Liska, J 3 ; Mercer, M 4 ; Tai, C 2 ; Buzzetti, R 5 ; Clement, M 6 ; Cos, X 7 ; Ji L 8 ; Kanumilli, N 9 ; Kerr, D 10   VIAFID ORCID Logo  ; Montanya, E 11   VIAFID ORCID Logo  ; Müller-Wieland, D 12 ; Ostenson, C G 13 ; Skolnik, N 14 ; Woo, V 15 ; Burlet, N 16 ; Greenberg, M 4 ; Samson, S I 17   VIAFID ORCID Logo 

 Evidation Health, San Mateo, USA (GRID:grid.492625.e); Emory University, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
 Evidation Health, San Mateo, USA (GRID:grid.492625.e) 
 Sanofi, Gentilly, France (GRID:grid.417924.d) 
 Sanofi Pasteur, Swiftwater, USA (GRID:grid.417555.7) (ISNI:0000 0000 8814 392X) 
 Sapienza University of Rome, Rome, Italy (GRID:grid.7841.a) 
 University of British Columbia, Armstrong, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830) 
 Grup de Recerca Epidemiològica en Diabetis des de l’Atenció Primària (DAP-CAT) Group, Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain (GRID:grid.17091.3e); Primary and Hospital Innovation Department, Innovation Office at Institut Català de la Salut, Barcelona, Spain (GRID:grid.22061.37) (ISNI:0000 0000 9127 6969) 
 Peking University People’s Hospital, Beijing, China (GRID:grid.411634.5) (ISNI:0000 0004 0632 4559) 
 Northenden Group Practice, Manchester, UK (GRID:grid.411634.5) 
10  Sansum Diabetes Research Institute, Santa Barbara, USA (GRID:grid.415743.0) 
11  Hospital Universitari Bellvitge-IDIBELL, CIBERDEM and University of Barcelona, Barcelona, Spain (GRID:grid.411129.e) (ISNI:0000 0000 8836 0780) 
12  University Hospital RWTH Aachen, Aachen, Germany (GRID:grid.412301.5) (ISNI:0000 0000 8653 1507) 
13  Karolinska Institute, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
14  Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, USA (GRID:grid.265008.9) (ISNI:0000 0001 2166 5843) 
15  University of Manitoba, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609) 
16  Sanofi, Paris, France (GRID:grid.417924.d); Kyowa Kirin International, Marlow, United Kingdom (GRID:grid.476499.1) 
17  Sanofi Pasteur, Lyon, France (GRID:grid.417924.d) 
Publication year
2021
Publication date
Dec 2021
Publisher
Nature Publishing Group
e-ISSN
23986352
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2573632842
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.